Abstract |
Background: Daratumumab is a monoclonal antibody, which targets CD38; an antigen expressed on malignant plasma cells in AL amyloidosis thus providing a rationale for its use.Method: Patients treated with daratumumab monotherapy (2016-2019) for relapsed/refractory systemic AL amyloidosis were identified from the database at the UK National Amyloidosis Centre.Results: Of 50 evaluable patients, haematological responses at 3 months were: CR - 19 (38%), VGPR - 14 (28%), PR - 9 (18%) and no response - 8 (16%). Median time to response was 1 (1-6) month. Of assessable patients, cardiac, renal and hepatic responses were seen in 43.8%, 25.0% and 0% of patients whilst progression occurred in 25.0%, 12.5% and 37.5% respectively. Patients achieving a CR had longer median OS (not reached vs. 22.7 months [95% CI 17.0-28.4 months]) (p = .036). Furthermore, patients achieving a rapid response (at 1 month) had a longer median PFS (not reached vs. 9 months [95% CI 5.8-12.2 months]) (p = .013).Conclusion: Daratumumab monotherapy is effective in multiply-relapsed systemic AL amyloidosis and should be considered, if available, in patients who have not received prior daratumumab therapy. Responses are achieved rapidly and overall response rate was 84%. CR predicts overall survival whilst speed of response is predictive of a longer PFS.
|
Authors | Oliver C Cohen, Maximillian H Brodermann, Iona J Blakeney, Shameem Mahmood, Sajitha Sachchithanantham, Sriram Ravichandran, Steven Law, Helen J Lachmann, Carol J Whelan, Rakesh Popat, Neil Rabin, Kwee Yong, Charalampia Kyriakou, Raakhee Shah, Simon Cheesman, Sarah Worthington, Philip Hawkins, Julian D Gillmore, Ashutosh D Wechalekar |
Journal | Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
(Amyloid)
Vol. 27
Issue 3
Pg. 200-205
(Sep 2020)
ISSN: 1744-2818 [Electronic] England |
PMID | 32408823
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- daratumumab
- ADP-ribosyl Cyclase 1
|
Topics |
- ADP-ribosyl Cyclase 1
(genetics)
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Disease-Free Survival
- Female
- Humans
- Immunoglobulin Light-chain Amyloidosis
(drug therapy, epidemiology, pathology)
- Male
- Middle Aged
- Plasma Cells
(metabolism, pathology)
- Progression-Free Survival
- Treatment Outcome
|